92 related articles for article (PubMed ID: 17071475)
1. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome.
Montero AJ; Estrov Z; Freireich EJ; Khouri IF; Koller CA; Kurzrock R
Leuk Lymphoma; 2006 Oct; 47(10):2049-54. PubMed ID: 17071475
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of low-dose interleukin-11 in patients with bone marrow failure.
Kurzrock R; Cortes J; Thomas DA; Jeha S; Pilat S; Talpaz M
J Clin Oncol; 2001 Nov; 19(21):4165-72. PubMed ID: 11689585
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.
Gordon MS; Nemunaitis J; Hoffman R; Paquette RL; Rosenfeld C; Manfreda S; Isaacs R; Nimer SD
Blood; 1995 Jun; 85(11):3066-76. PubMed ID: 7538815
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
6. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases.
Bourgeois E; Caulier MT; Rose C; Dupriez B; Bauters F; Fenaux P
Leukemia; 2001 Jun; 15(6):950-3. PubMed ID: 11417482
[TBL] [Abstract][Full Text] [Related]
7. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.
Tsimberidou AM; Giles FJ; Khouri I; Bueso-Ramos C; Pilat S; Thomas DA; Cortes J; Kurzrock R
Ann Oncol; 2005 Jan; 16(1):139-45. PubMed ID: 15598951
[TBL] [Abstract][Full Text] [Related]
8. Use of interleukin-11 to stimulate platelet production in myelodysplastic syndromes.
Valent P
Leuk Lymphoma; 2006 Oct; 47(10):1999-2001. PubMed ID: 17071464
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
[TBL] [Abstract][Full Text] [Related]
10. CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopenia.
Garcia-Manero G; Scott BL; Cogle CR; Boyd TE; Kambhampati S; Hetzer J; Dong Q; Kumar K; Ukrainskyj SM; Beach CL; Skikne BS
Leuk Res; 2018 Sep; 72():79-85. PubMed ID: 30114559
[TBL] [Abstract][Full Text] [Related]
11. [Expert consensus on rational use of recombinant human IL-11 for thrombocytopenia in solid tumor patients].
Zhonghua Zhong Liu Za Zhi; 2010 Dec; 32(12):948-9. PubMed ID: 21223808
[No Abstract] [Full Text] [Related]
12. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia.
Nimer SD; Paquette RL; Ireland P; Resta D; Young D; Golde DW
Exp Hematol; 1994 Aug; 22(9):875-80. PubMed ID: 8062886
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
14. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
15. The management and outcomes of patients with myelodysplastic syndrome with persistent severe thrombocytopenia: An observational single centre registry study.
Vijenthira A; Premkumar D; Callum J; Lin Y; Wells RA; Chodirker L; Lenis M; Mamedov A; Buckstein R
Leuk Res; 2019 Jan; 76():76-81. PubMed ID: 30580105
[TBL] [Abstract][Full Text] [Related]
16. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
[TBL] [Abstract][Full Text] [Related]
17. The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor).
Kaye JA
Stem Cells; 1996; 14 Suppl 1():256-60. PubMed ID: 11012229
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome.
Hsu HC; Lee YM; Tsai WH; Jiang ML; Ho CH; Ho CK; Wang SY
Oncology; 2002; 63(1):64-9. PubMed ID: 12187073
[TBL] [Abstract][Full Text] [Related]
20. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
